65.19

0.87% 0.56

After Hours: 65.19

Halozyme Therapeutics Inc (HALO)

Overview News Price History Option Chain Financials Why HALO Down? Discussions Forecast

Halozyme Therapeutics Inc stock is traded at $65.19, with a volume of 1.41M. It is up +0.87% in the last 24 hours and down -11.11% over the past month. Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Previous Close:

$64.63

Open:

$64.1

24h Volume:

1.41M

Relative Volume:

0.69

Market Cap:

$7.63B

Revenue:

$947.36M

Net Income/Loss:

$392.47M

P/E Ratio:

21.59

EPS:

3.02

Net Cash Flow:

$392.71M

1W Performance:

-1.45%

1M Performance:

-11.11%

6M Performance:

+6.14%

1Y Performance:

+28.91%

1-Day Range:

$63.84

$65.49

1-Week Range:

$63.84

$66.99

52-Week Range:

$42.01

$79.50

Halozyme Therapeutics Inc Stock (HALO) Company Profile

Name

Halozyme Therapeutics Inc

Sector

Healthcare (1135)

Industry

Biotechnology (635)

Phone

(858) 794-8889

Address

12390 EL CAMINO REAL, SAN DIEGO, CA

Employee

350

Twitter

@halozymeinc

Next Earnings Date

2025-02-18

Latest SEC Filings

HALO's Discussions on Twitter

Compare HALO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HALO Halozyme Therapeutics Inc	65.19	7.56B	947.36M	392.47M	392.71M	3.02
VRTX Vertex Pharmaceuticals Inc	425.57	107.66B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	651.80	68.74B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	456.04	58.93B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	818.50	50.51B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	189.60	41.29B	447.02M	-1.18B	-868.57M	-6.1812

Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-14-25	Upgrade	Leerink Partners	Underperform → Market Perform
Aug-06-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jul-10-25	Resumed	Goldman	Neutral
May-14-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
May-13-25	Downgrade	Leerink Partners	Market Perform → Underperform
Oct-07-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-19-24	Downgrade	JP Morgan	Overweight → Neutral
Jun-07-24	Downgrade	Piper Sandler	Overweight → Neutral
Feb-29-24	Initiated	TD Cowen	Outperform
Jul-24-23	Downgrade	Goldman	Buy → Neutral
Jul-24-23	Initiated	H.C. Wainwright	Buy
May-10-23	Upgrade	Piper Sandler	Neutral → Overweight
Mar-27-23	Resumed	Berenberg	Buy
Mar-16-23	Downgrade	SVB Securities	Outperform → Market Perform
Dec-21-22	Resumed	Morgan Stanley	Overweight
Nov-28-22	Initiated	Wells Fargo	Overweight
Sep-09-22	Initiated	Morgan Stanley	Overweight
May-23-22	Initiated	SVB Leerink	Outperform
Jun-14-21	Initiated	Evercore ISI	Outperform
May-17-21	Initiated	SVB Leerink	Outperform
May-11-21	Downgrade	Piper Sandler	Overweight → Neutral
Jan-21-21	Reiterated	The Benchmark Company	Buy
Dec-17-20	Initiated	Berenberg	Buy
Sep-14-20	Resumed	JP Morgan	Overweight
Jul-01-20	Initiated	The Benchmark Company	Buy
Feb-05-20	Upgrade	Piper Sandler	Neutral → Overweight
Jan-09-20	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jan-08-20	Initiated	Goldman	Buy
Nov-05-19	Upgrade	Barclays	Underweight → Equal Weight
Oct-19-18	Resumed	Piper Jaffray	Neutral
May-11-18	Downgrade	Barclays	Equal Weight → Underweight
Jan-24-18	Initiated	Goldman	Neutral
Oct-16-17	Reiterated	Piper Jaffray	Overweight
Jan-06-17	Downgrade	Citigroup	Buy → Neutral
Nov-03-16	Initiated	Deutsche Bank	Buy
Dec-04-15	Initiated	Wells Fargo	Outperform
Nov-18-15	Initiated	Citigroup	Buy
Sep-22-15	Initiated	Barclays	Overweight
Jun-22-15	Reiterated	JP Morgan	Overweight
Mar-03-15	Reiterated	UBS	Buy
Feb-18-15	Reiterated	MLV & Co	Buy
Jan-08-15	Reiterated	MLV & Co	Buy

View All

Halozyme Therapeutics Inc Stock (HALO) Latest News

12:52 PM

Can Halozyme Therapeutics Inc. stock continue upward trend2025 Earnings Impact & Fast Moving Trade Plans - newser.com

12:52 PM

12:50 PM

Will Halozyme Therapeutics Inc. price bounce be sustainableMarket Risk Report & Reliable Volume Spike Alerts - newser.com

12:50 PM

Nov 02, 2025

Using Python tools to backtest Halozyme Therapeutics Inc. strategiesWeekly Trend Recap & Technical Pattern Based Signals - newser.com

Nov 02, 2025

Will Halozyme Therapeutics Inc. stock benefit from upcoming earnings reportsWeekly Stock Report & Low Drawdown Investment Strategies - newser.com

Nov 02, 2025

Halozyme Therapeutics (HALO) Anticipates Strong Q3 Earnings Grow - GuruFocus

Nov 02, 2025

Why Halozyme Therapeutics Inc. stock could be next big winnerShort Setup & Real-Time Volume Triggers - newser.com

Nov 02, 2025

Retirement Systems of Alabama Sells 4,246 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat

Nov 02, 2025

Combining price and volume data for Halozyme Therapeutics Inc.Layoff News & Expert Approved Momentum Trade Ideas - newser.com

Nov 02, 2025

AlphaQuest LLC Purchases 5,133 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat

Nov 02, 2025

Will Halozyme Therapeutics Inc. stock benefit from infrastructure spendingCPI Data & Proven Capital Preservation Methods - newser.com

Nov 02, 2025

Nov 01, 2025

HALOZYME THERAPEUTICS Earnings Preview: Recent $HALO Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative

Nov 01, 2025

Will Halozyme Therapeutics Inc. stock see PE expansionWeekly Investment Recap & AI Based Buy and Sell Signals - newser.com

Nov 01, 2025

What insider trading reveals about Halozyme Therapeutics Inc. stockJuly 2025 PostEarnings & Reliable Momentum Entry Alerts - newser.com

Nov 01, 2025